Elevated Levels of MMP-9 in Untreated Patients with Stage I Essential Hypertension

REFERENCES

• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90(3):251–262.
   PubMed Web of Science ®Google Scholar
• Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110(5):625–632.
   PubMed Web of Science ®Google Scholar
• Thompson RW, Holmes DR, Mertens RA, . Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96(1):318–326.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Hayakawa T. Assaying growth factor activity of tissue inhibitors of metalloproteinases. Methods Mol Biol 2001; 151:533–537.
   PubMedGoogle Scholar
• Muhs BE, Patel S, Yee H, Marcus S, Shamamian P. Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis. J Surg Res 2003; 109(2):110–117.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748:501–507.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92(2):402–406.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94(6):2493–2503.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Poirier O, . Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107(12):1579–1585.
   PubMed Web of Science ®Google Scholar
• Montaner J, Molina CA, Monasterio J, . Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107(4):598–603.
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Evans JC, Benjamin EJ, . Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109(23):2850–2856.
   PubMed Web of Science ®Google Scholar
• Fukuda D, Shimada K, Tanaka A, . Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97(2):175–180.
   PubMed Web of Science ®Google Scholar
• Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008; 31(9):413–418.
   PubMed Web of Science ®Google Scholar
• Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005; 96(3): 339–345.
   PubMed Web of Science ®Google Scholar
• Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007; 30(10):959–963.
   PubMed Web of Science ®Google Scholar
• Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17(9):764–769.
   PubMed Web of Science ®Google Scholar
• Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75(1): 43–47.
   PubMed Web of Science ®Google Scholar
• Zhou S, Feely J, Spiers JP, Mahmud A. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 2007; 21(11): 861–867.
   PubMed Web of Science ®Google Scholar
• Yasmin SW, McEniery CM, Wallace S, . Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25(2):372.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, . Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12):1462–1536.
   PubMed Web of Science ®Google Scholar
• Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19(2):149–154.
   PubMed Web of Science ®Google Scholar
• Laurent S, Cockcroft J, Van Bortel L, . Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27(21):2588–2605.
   PubMed Web of Science ®Google Scholar
• Kai H, Ikeda H, Yasukawa H, . Peripheral blood levels of matrix metalloproteases-2 and ‐9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32(2):368–372.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Aznaouridis K, Dima I, . Negative association between serum levels of matrix metalloproteinases-2 and ‐9 and aortic stiffness in healthy adults. Int J Cardiol 2007; 122(3): 232–238.
   PubMed Web of Science ®Google Scholar
• Odenbach J, Wang X, Cooper S, . MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011; 57(1):123–130.
   PubMed Web of Science ®Google Scholar
• Laviades C, Varo N, Fernandez J, . Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98(6):535–540.
   PubMed Web of Science ®Google Scholar
• Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40(2):136–141.
   PubMed Web of Science ®Google Scholar
• Szmigielski C, Raczkowska M, Styczynski G, Pruszczyk P, Gaciong Z. Metabolism of collagen is altered in hypertensives with increased intima media thickness. Blood Press 2006; 15(3):157–163.
   PubMed Web of Science ®Google Scholar
• Papadopoulos DP, Thomopoulos C, Perrea D, . Changes of metalloproteinases profile in patients with masked hypertension. Angiology 2009; 60(6):757–762.
   PubMed Web of Science ®Google Scholar
• Papadopoulos DP, Makris TK, Krespi PG, . Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure. Eur Cytokine Netw 2005; 16(3): 211–214.
   PubMed Web of Science ®Google Scholar
• Marchesi C, Dentali F, Nicolini E, . Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 2011; 30:3–16.
   Web of Science ®Google Scholar